Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine: Human Model to Assess Central and Peripheral Effects of Dosing

• Published in: Journal of clinical psychopharmacology Vol. 36; no. 6; p. 675
• Main Authors: Bieck, Peter R, Leibowitz, Mark, Lachno, D Richard, Ledent, Edouard, Padich, Robert, Jhee, Stan
• Format: Journal Article
• Language: English
• Published: United States 01.12.2016
• Subjects: Adrenergic Uptake Inhibitors - administration & dosage; Adrenergic Uptake Inhibitors - pharmacokinetics; Adrenergic Uptake Inhibitors - pharmacology; Adult; Area Under Curve; Atomoxetine Hydrochloride - administration & dosage; Atomoxetine Hydrochloride - pharmacokinetics; Atomoxetine Hydrochloride - pharmacology; Biomarkers - blood; Biomarkers - cerebrospinal fluid; Brain-Derived Neurotrophic Factor - cerebrospinal fluid; Female; Humans; Male; Methoxyhydroxyphenylglycol - analogs & derivatives; Methoxyhydroxyphenylglycol - blood; Methoxyhydroxyphenylglycol - cerebrospinal fluid; Middle Aged; Norepinephrine - metabolism; Norepinephrine Plasma Membrane Transport Proteins - antagonists & inhibitors; Norepinephrine Plasma Membrane Transport Proteins - metabolism; Young Adult

To assess the primary metabolite of norepinephrine, 3,4-dihydroxyphenylglycol (DHPG), as a sensitive biomarker for norepinephrine transporter (NET) function and the relationship of DHPG measured peripherally and centrally, NET was antagonized with 80 mg/d atomoxetine for 18 days. Twelve healthy subj...